2013
DOI: 10.1016/j.bbr.2013.08.017
|View full text |Cite
|
Sign up to set email alerts
|

Ketamine increases striatal dopamine release and hyperlocomotion in adult rats after postnatal functional blockade of the prefrontal cortex

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

8
41
0

Year Published

2014
2014
2023
2023

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 39 publications
(49 citation statements)
references
References 83 publications
8
41
0
Order By: Relevance
“…These ketamine-induced effects are mediated by both descending and ascending fibers projecting to the VTA (Morikawa and Paladini 2011). There is also a large body of evidence, gained via both in vivo and in vitro techniques, showing that ketamine increases DA release and blocks DA reuptake in the dorsal striatum (Keita et al 1996; Tso et al 2004; Usun et al 2013), nucleus accumbens (Hancock and Stamford 1999; Witkin et al 2016), and prefrontal cortex (Lindefors et al 1997; Lorrain et al 2003; see Smith et al 1981). In some cases, the ability of ketamine to modulate DA release is attributed to actions involving afferent inhibitory interneurons in DA target areas (Verma and Moghaddam 1996; Lorrain et al 2003; Usun et al 2013; see also Can et al 2016), while others suggest that ketamine acts as an indirect DA agonist (Irifune et al 1991; Nishimura et al 1998; Hancock and Stamford 1999).…”
Section: Introductionmentioning
confidence: 99%
“…These ketamine-induced effects are mediated by both descending and ascending fibers projecting to the VTA (Morikawa and Paladini 2011). There is also a large body of evidence, gained via both in vivo and in vitro techniques, showing that ketamine increases DA release and blocks DA reuptake in the dorsal striatum (Keita et al 1996; Tso et al 2004; Usun et al 2013), nucleus accumbens (Hancock and Stamford 1999; Witkin et al 2016), and prefrontal cortex (Lindefors et al 1997; Lorrain et al 2003; see Smith et al 1981). In some cases, the ability of ketamine to modulate DA release is attributed to actions involving afferent inhibitory interneurons in DA target areas (Verma and Moghaddam 1996; Lorrain et al 2003; Usun et al 2013; see also Can et al 2016), while others suggest that ketamine acts as an indirect DA agonist (Irifune et al 1991; Nishimura et al 1998; Hancock and Stamford 1999).…”
Section: Introductionmentioning
confidence: 99%
“…Finally, recently obtained data showed that animals that underwent early-life inactivation of the prefrontal cortex also displayed greater behavioral and neurochemical reactivity to D-amphetamine (Meyer and Louilot, 2012) and ketamine, at subanesthetic doses (Usun et al, 2013). This is of particular interest given that both these drugs are known to induce psychotic symptoms in healthy individuals and to worsen such symptoms in patients with schizophrenia.…”
Section: Discussionmentioning
confidence: 99%
“…In addition, results obtained in our laboratory, which are discussed in detail below, showed that neonatal transient TTX inactivation of the entorhinal cortex, ventral subiculum or prefrontal cortex induced disturbed dopaminergic and behavioral responses related to latent inhibition (LI) in adulthood (Peterschmitt et al, 2007; Meyer et al, 2009; Meyer and Louilot, 2011, 2012). It is important to note that no lesions or macroscopic anatomical changes have been observed in the aforementioned studies following neonatal TTX inactivation (Lipska et al, 2002; Peterschmitt et al, 2007; Meyer et al, 2009; Brooks et al, 2011; Meyer and Louilot, 2011, 2012; Brooks et al, 2012; Usun et al, 2013). Taken together, functional disconnection models appear to be a relevant conceptual approach to animal modeling for some aspects of the pathophysiology of schizophrenia and without inducing any major anatomical lesion.…”
Section: Introductionmentioning
confidence: 98%
“…This may imply that ketamine may have larger half maximal inhibitory (ID 50 ) when compared to the other two; however, it needs further investigations. The explanation could be that ketamine, as an NMDA noncompetitive antagonist, can inhibit the reuptake of dopamine and increase striatal dopamine release [28, 29]. Dopaminergic response induced by ketamine results in excess dopamine into the synaptic clefts of dopaminergic neurons and then reduces the specific binding of [ 18 F]FDOPA.…”
Section: Discussionmentioning
confidence: 99%